drugset / Trial / NCT02783599
A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate potential biomarkers and method of action, efficacy and safety of olaratumab in participants with soft tissue sarcoma (STS).
Timeline
- Start
- 2016-10-11
- Primary completion
- 2018-07-05
- Completion
- 2018-07-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olaratumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Background | Doxorubicin | Other / unclassified | 75 mg/m2 | Intravenous |